Vericel (Vericel) Price-to-Tangible-Book

: 9.91 (As of Today)

View and export this data going back to 1997. Start your Free Trial

As of today (2024-04-23), Vericel's share price is $45.40. Vericel's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $4.58. Hence, Vericel's Price to Tangible Book Ratio of today is 9.91.

The historical rank and industry rank for Vericel's Price-to-Tangible-Book or its related term are showing as below:

VCEL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.74 Med: 7.78 Max: 10.81
Current: 9.91

During the past 13 years, Vericel's highest Price to Tangible Book Ratio was 10.81. The lowest was 6.74. And the median was 7.78.

VCEL's Price-to-Tangible-Book is ranked worse than
87.88% of 1221 companies
in the Biotechnology industry
Industry Median: 2.67 vs VCEL: 9.91

A closely related ratio is called PB Ratio. As of today, Vericel's share price is $45.40. Vericel's Book Value per Sharefor the quarter that ended in Dec. 2023 was $4.72. Hence, Vericel's P/B Ratio of today is 9.61.

Vericel Price-to-Tangible-Book Historical Data

The historical data trend for Vericel's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

7.03

10.54

10.81

6.74

7.78

Vericel Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book																6.74	7.46	9.33	8.10	7.78

Competitive Comparison

For the Biotechnology subindustry, Vericel's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vericel Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, Vericel's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Vericel's Price-to-Tangible-Book falls into.

Vericel Price-to-Tangible-Book Calculation

Vericel's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	45.40	/	4.58
	=	9.91

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Vericel Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Vericel's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Vericel (Vericel) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

ATQP:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.vcel.com

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Executives

Dominick Colangelo	director, officer: President and CEO	1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Zerbe Robert L Md	director
Paul K Wotton	director	C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Sean C. Flynn	officer: SVP, General Counsel	C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Michael Halpin	officer: Chief Operating Officer	C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Jonathan Mark Hopper	officer: Chief Medical Officer	64 SIDNEY STREET, CAMBRIDGE MA 02139
Jonathan Siegal	officer: Principal Accounting Officer	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Lisa Wright	director	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Mara Joseph Anthony Jr	officer: Chief Financial Officer	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Sandra Pennell	officer: VP and Corporate Controller	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel	officer: CFO & VP , Corp. Development	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando	officer: Chief Operating Officer	P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino	director	PO BOX 376, LOBBY L., ANN ARBOR MI 48105
Consonance Capital Management Lp	10 percent owner	1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK NY 10019